Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
PRLD on Nasdaq
Shares outstanding
44,162,869
Price per share
$1.60
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
27,161,835
Total reported value
$39,111,943
% of total 13F portfolios
0%
Share change
-26,120
Value change
+$249,046
Number of holders
45
Price from insider filings
$1.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 24% $8,010,575 10,269,968 Baker Bros. Advisors LP 12 Jun 2025
Vaddi Krishna 14% +43% $3,902,682 +$554,312 6,397,839 +17% Vaddi Krishna 31 Mar 2025
INCYTE CORP 9.9% $6,295,859 4,372,124 INCYTE CORP 03 Nov 2025

As of 30 Sep 2025, 45 institutional investors reported holding 27,161,835 shares of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD). This represents 62% of the company’s total 44,162,869 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 25% 10,909,256 0% 0.38% $15,709,329
BAKER BROS. ADVISORS LP 23% 10,123,824 0% 0.11% $14,578,307
MILLENNIUM MANAGEMENT LLC 2.6% 1,147,044 +362% 0% $1,651,743
VANGUARD GROUP INC 2.2% 992,854 +6.5% 0% $1,429,710
PRICE T ROWE ASSOCIATES INC /MD/ 2% 876,338 -5.5% 0% $1,262,000
RENAISSANCE TECHNOLOGIES LLC 1.2% 544,000 -6.5% 0% $783,360
ACADIAN ASSET MANAGEMENT LLC 1.2% 540,565 0% 0% $777,000
MORGAN STANLEY 0.64% 284,203 -0.06% 0% $409,252
BlackRock, Inc. 0.6% 264,973 -39% 0% $381,562
TWO SIGMA ADVISERS, LP 0.5% 222,700 -1% 0% $320,688
GEODE CAPITAL MANAGEMENT, LLC 0.49% 217,568 0% 0% $313,366
TD Asset Management Inc 0.36% 160,652 0% 0% $231,339
TWO SIGMA INVESTMENTS, LP 0.34% 152,233 -1.8% 0% $219,216
Shay Capital LLC 0.23% 100,000 +33% 0.03% $144,000
STATE STREET CORP 0.22% 97,592 0% 0% $140,532
GOLDMAN SACHS GROUP INC 0.18% 79,327 -47% 0% $114,231
GSA CAPITAL PARTNERS LLP 0.17% 75,161 +5.3% 0.01% $108,000
MANUFACTURERS LIFE INSURANCE COMPANY, THE 0.16% 69,252 0% 0% $99,723
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.12% 53,500 -40% 0% $77,040
NORTHERN TRUST CORP 0.08% 36,421 -4.5% 0% $52,446
JANE STREET GROUP, LLC 0.08% 34,822 -62% 0% $50,144
Cerity Partners LLC 0.08% 34,333 -5.7% 0% $49,440
PRUDENTIAL FINANCIAL INC 0.06% 25,840 0% $37,210
HRT FINANCIAL LP 0.04% 16,901 0% $24,000
XTX Topco Ltd 0.04% 15,578 -63% 0% $22,432

Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 27,161,835 $39,111,943 +$249,046 $1.44 45
2025 Q2 27,187,955 $21,995,839 -$2,401,938 $0.81 49
2025 Q1 30,289,302 $23,267,261 -$2,260,764 $0.77 56
2024 Q4 32,132,488 $40,959,472 -$12,964,361 $1.28 59
2024 Q3 35,754,682 $74,021,418 +$3,113,834 $2.07 69
2024 Q2 33,917,161 $129,220,384 -$1,301,517 $3.81 59
2024 Q1 34,196,671 $162,092,671 -$2,330,945 $4.74 55
2023 Q4 34,725,223 $148,268,972 -$6,549,040 $4.27 55
2023 Q3 36,614,209 $113,137,981 +$1,036,813 $3.09 57
2023 Q2 36,273,689 $163,232,997 +$31,251,103 $4.50 52
2023 Q1 31,510,168 $179,608,477 +$1,734,917 $5.70 53
2022 Q4 31,178,530 $188,299,136 -$4,386,482 $6.04 58
2022 Q3 31,792,416 $210,139,653 -$5,202,354 $6.61 48
2022 Q2 32,222,583 $168,195,689 -$6,709,406 $5.22 51
2022 Q1 32,508,790 $224,341,986 -$9,980,248 $6.90 60
2021 Q4 35,083,728 $436,791,391 -$27,306,553 $12.45 71
2021 Q3 35,930,334 $1,122,824,157 +$46,348,794 $31.25 59
2021 Q2 34,458,562 $986,645,054 +$53,288,480 $28.63 57
2021 Q1 32,521,326 $1,409,146,760 -$97,752,682 $43.33 59
2020 Q4 34,651,473 $2,474,381,581 +$135,766,501 $71.55 50
2020 Q3 33,322,061 $999,836,330 +$999,835,543 $30.13 38